Microcap Ledger

Tickers · $BCDA

BioCardia, Inc. $BCDA

By Microcap Ledger desk · CIK 0000925741

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Biological Products, (No Diagnostic Substances)
Headquarters
Sunnyvale, CA
Fiscal year end
December 31
Shares outstanding
15,138,782 [10-Q 2026-08-12]
as of 2026-08-11

Sources: [10-K 2026-03-24]

What the company doesAI summary of filing

BioCardia is a clinical-stage company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases. The company's lead program, CardiAMP, uses patients' own bone marrow cells delivered via a proprietary catheter system to treat ischemic heart failure and chronic myocardial ischemia; a Phase III trial for heart failure did not meet its primary endpoint but showed benefits in a biomarker-positive subgroup, and the company is pursuing FDA approval discussions. The company also develops CardiALLO, an off-the-shelf allogeneic mesenchymal stem cell therapy for heart failure in early-stage clinical trials, and PulmALLO for acute respiratory distress syndrome. Additionally, BioCardia licenses its Helix biotherapeutic delivery system to partners and manufactures and sells Morph vascular access catheters. [10-K 2026-03-24]

Segments: CardiAMP autologous cell therapy (heart failure and chronic myocardial ischemia), CardiALLO allogeneic MSC therapy (heart failure), PulmALLO allogeneic MSC therapy (acute respiratory distress syndrome), Helix biotherapeutic delivery system and Morph vascular access products

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026—−$3.87M −$3.39M$4.12M[10-Q 2026-08-12]
FY ended Dec 2025$0.00−$8.23M −$7.44M$2.50M[10-K 2026-03-24]
FY ended Dec 2024$58.0K−$7.95M −$7.89M$2.37M[10-K 2026-03-24]
Quarterly cash burn
−$1.70M
Cash runway Estimate
~7.3 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-054,584,285[10-Q 2024-11-13]
2025-03-264,680,005[10-K 2025-03-26]
2025-05-135,177,890[10-Q 2025-05-14]
2025-08-085,801,224[10-Q/A 2025-10-29]
2025-11-1110,612,734[10-Q 2025-11-12]
2026-03-2410,940,372[10-K 2026-03-24]
2026-05-1311,374,724[10-Q 2026-05-15]
2026-08-1115,138,782[10-Q 2026-08-12]
Shelf registration
S-1 filed 2025-09-16; declared effective 2025-09-18 [S-1 2025-09-16]

Listing status

Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-08-218-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-08-21]
2026-06-128-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-06-12]
2026-04-158-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-04-15]
2025-09-248-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-09-24]
2025-04-048-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-04-04]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-29Altman Peterbuy1,000$1.03[4 2026-09-30]
2026-09-23Altman Peterbuy1,900$1.05[4 2026-09-23]
2026-09-03Altman Peterbuy800$1.09[4 2026-09-04]
2026-08-17Altman Peterbuy5,400$0.93[4 2026-08-18]
2026-08-13Altman Peterbuy1,900$0.92[4 2026-08-13]
2026-07-29Altman Peterbuy5,000$0.78[4 2026-07-29]
2026-07-17Altman Peterbuy500$0.83[4 2026-07-20]
2026-07-15Altman Peterbuy1,500$0.86[4 2026-07-15]
2026-07-14Altman Peterbuy2,800$0.88[4 2026-07-15]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-078-KOther events
2026-10-018-KOther events
2026-09-238-KOther events
2026-09-218-KOther events
2026-09-108-KOther events
2026-08-248-KRegulation FD disclosure
2026-08-218-KListing notice or transfer
2026-08-128-KResults of operations
2026-08-1210-QQuarterly report
2026-06-188-KRegulation FD disclosure
2026-06-128-KListing notice or transfer
2026-06-088-KOther events

Facts as of . Small caps move fast; check the latest filings.